C4 Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
C4 Therapeutics, Inc. (CCCC) had Debt Securities, Available-for-sale, Unrealized Loss Position of $111.93 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-02-26
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $111.93M.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $67.41M.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $108.59M.
- 2023-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $241.49M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2025-12-31 | $111.93M 10-K · filed 2026-02-26 |
| 2024-12-31 | $67.41M 10-K · filed 2026-02-26 |
| 2023-12-31 | $108.59M 10-K · filed 2025-02-27 |
| 2023-03-31 | $241.49M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $289.43M 10-K · filed 2024-02-22 |
| 2022-09-30 | $309.04M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $339.11M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $373.15M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $365.50M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |